PK of new molecules [Design Issues]

posted by nobody – 2017-04-18 16:19 (2557 d 19:55 ago) – Posting: # 17247
Views: 3,656

Hi!

What are we talking about? First-in-man? Mass balance? Dose-escalation in healthy volunteers?

If you have no experience (especially with the allometric scaling for first dose and necessary in vitro studies for tox/safety pharmacology/pk/metabolism) I would not even think about designing such trials based on "internet knowledge". Humans are not rats and rabbits.

Kindest regards, nobody

Complete thread:

UA Flag
Activity
 Admin contact
22,987 posts in 4,824 threads, 1,662 registered users;
88 visitors (0 registered, 88 guests [including 4 identified bots]).
Forum time: 12:14 CEST (Europe/Vienna)

The only way to comprehend what mathematicians mean by Infinity
is to contemplate the extent of human stupidity.    Voltaire

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5